TABLE 1.

Workshop Speakers and Presentations^a

Speakers	Representing/affiliation	Title
C. Norman Coleman, MD	National Cancer Institute	Poly pharmacy: How might this need be considered for a major nuclear or radiological incident that could produce the acute radiation syndrome?
Steven A. Adams, MPH	ASPR	Strategic National Stockpile, support for the response to a nuclear incident
Christie M. Orschell, PhD	Indiana University School of Medicine	Defining the hematopoietic acute radiation syndrome and the delayed effects of acute radiation exposure in murine models
Thomas MacVittie, PhD	University of Maryland School of Medicine	The acute radiation syndrome in the nonhuman primate: Is ARS multi-organ injury (MOI) linked to the MOI characteristic of the delayed effects of acute radiation exposure?
J. Mark Cline, DVM, PhD, DACVP	Wake Forest School of Medicine	Multisystemic delayed effects of acute radiation exposure in nonhuman primates
George (Joe) Cox, PhD	Bolder Biotechnology, Inc.	Improving survival in a mouse H-ARS model using combinations of hematopoietic growth factors and an ACE inhibitor
Meetha Medhora, PhD	Medical College of Wisconsin	Enhanced mitigation of radiation-induced injuries by combining angiotensin-converting enzyme (ACE) inhibitors with other countermeasures
Juliann Kiang, PhD	AFRRI	Combined drugs with the pegylated-G-CSF therapy to enhance survival and against multi-organ injury after irradiation alone or combined with wound trauma
Yon Yu, PharmD	CDC	Regulatory considerations for emergency use of stockpiled medical countermeasures
Mario Sampson, PharmD	CDER, FDA	Clinical pharmacology considerations for products developed for acute radiation syndrome
Adebayo Laniyonu, PhD	CDER, FDA	Product development for acute radiation syndrome: Nonclinical considerations for animal rule efficacy studies

^aWorkshop participants had an opportunity to review this meeting report prior to journal submission.